ICCM
- IceCure Medical Ltd
()
Overview
Company Summary
IceCure Medical Ltd (ICCM) is a medical technology company that specializes in the development and commercialization of advanced cryoablation technology. Their primary focus is on treating tumors, specifically in the field of breast cancer.
The company's flagship product, ProSense, uses a minimally invasive procedure called cryoablation, which destroys tumors by freezing them. This technique utilizes extremely cold temperatures to create ice crystals within the tumor, causing cellular damage and ultimately leading to its destruction.
ICCM's ProSense system comprises a proprietary probe that is inserted into the tumor, delivering liquid nitrogen to freeze the tissue. This innovative technology has several advantages over traditional surgical methods. It is non-invasive, requires no hospitalization, and can be performed on an outpatient basis. Additionally, it provides a less painful and quicker recovery process, with minimal scarring.
The ProSense system has gained significant attention and adoption worldwide, as it offers an effective alternative for early-stage breast cancer patients who would prefer to avoid surgery or are not suitable candidates for it. It has also shown potential in treating benign breast tumors, fibroadenomas, and other conditions that may require intervention.
In addition to breast cancer treatment, ICCM is actively expanding its product portfolio to address other types of cancer, including liver, kidney, and lung tumors. They continue to invest in research and development to refine their cryoablation technology, making it applicable to a wider range of cancers and improving patient outcomes.
Overall, IceCure Medical Ltd is dedicated to advancing the field of cryoablation and providing innovative solutions for cancer treatment, offering patients a safer, less invasive, and more comfortable alternative to traditional surgical procedures.